BRCA1 and ovarian carcinoma: Epithelial ovarian cancer patients with BRCA1/2 mutations exhibit a superior response to platinum-based chemotherapies compared with those without BRCA1/2 mutations, resulting in improved survival rates, despite the disease being diagnosed at an advanced stage and higher grade [8].